Funding for this research was provided by:
Received: 5 December 2020
Accepted: 15 March 2021
First Online: 2 April 2021
: A written informed consent was obtained from all patients or legal representatives of the study participants. Patients could be included within 14 days after first sampling if they were unable to give consent due to disease severity at time of admission. Patients could at any time withdraw from the study. All samples obtained from patients were destroyed if consent did not arrive to the laboratory within 14 days post inclusion or if consent was withdrawn. The study received approval from the Regional Ethical Review Board Uppsala, Sweden, Sep. 2014 (dnr 2014/193).
: Not applicable.
: The authors declare that they have no competing interests.